Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335842 | 1.00 | ADRB2 (0.39) | ADRB2OPRM1SSTR1SSTR2SSTR4 | |
| SCHEMBL25339489 | 0.88 | ADRB2 (0.42) | ADRB2OPRM1SSTR1SSTR2SSTR4 | |
| SCHEMBL31314088 | 0.86 | PARP1 (0.40) | — | |
| SCHEMBL30543718 | 0.86 | PARP1 (0.40) | — | |
| SCHEMBL25339303 | 0.86 | PARP1 (0.40) | — | |
| SCHEMBL25340065 | 0.85 | ADRB2 (0.36) | ADRB2OPRM1SSTR1SSTR2SSTR4 | |
| SCHEMBL25339166 | 0.85 | ADRB2 (0.36) | ADRB2OPRM1SSTR1SSTR2SSTR4 | |
| SCHEMBL25339428 | 0.79 | ADRB2 (0.33) | ADRB2OPRM1ALDH1A1HSD11B1 | |
| SCHEMBL25338261 | 0.79 | ADRB2 (0.33) | ADRB2OPRM1ALDH1A1HSD11B1 | |
| SCHEMBL25339786 | 0.76 | ADRB2 (0.39) | ADRB2OPRM1HTR1ADRD2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADRB2 4578/4885OPRM1 4472/4885SSTR1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.